Is It Safe to Restart Antivascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma after Cardiac Ischemia?
Agents targeting vascular endothelial growth factor (VEGF) represent active drugs in treating patients with advanced renal cell carcinoma (RCC). Studies have shown that sunitinib and axitinib can be associated with cardiac toxicity. Whether these agents should be restarted in patients who experience...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2015/817578 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564464562470912 |
|---|---|
| author | Bo Zhao Laura S. Wood Karen James Brian I. Rini |
| author_facet | Bo Zhao Laura S. Wood Karen James Brian I. Rini |
| author_sort | Bo Zhao |
| collection | DOAJ |
| description | Agents targeting vascular endothelial growth factor (VEGF) represent active drugs in treating patients with advanced renal cell carcinoma (RCC). Studies have shown that sunitinib and axitinib can be associated with cardiac toxicity. Whether these agents should be restarted in patients who experience cardiac ischemia remains uncertain. Here, we present three patients with metastatic RCC who restarted sunitinib or axitinib after intervention of active ischemic cardiac disease without causing subsequent relevant cardiac events. This experience suggests that these agents can be continued after management of cardiac ischemia. |
| format | Article |
| id | doaj-art-42e72c5389024f66b21e24646a1cef7b |
| institution | Kabale University |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-42e72c5389024f66b21e24646a1cef7b2025-02-03T01:10:55ZengWileyCase Reports in Oncological Medicine2090-67062090-67142015-01-01201510.1155/2015/817578817578Is It Safe to Restart Antivascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma after Cardiac Ischemia?Bo Zhao0Laura S. Wood1Karen James2Brian I. Rini3Department of Hematology and Oncology, Cleveland Clinic, 9500 Euclid Avenue R35, Cleveland, OH 44195, USADepartment of Hematology and Oncology, Cleveland Clinic, 9500 Euclid Avenue R35, Cleveland, OH 44195, USADepartment of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue J3-4, Cleveland, OH 44195, USADepartment of Hematology and Oncology, Cleveland Clinic, 9500 Euclid Avenue R35, Cleveland, OH 44195, USAAgents targeting vascular endothelial growth factor (VEGF) represent active drugs in treating patients with advanced renal cell carcinoma (RCC). Studies have shown that sunitinib and axitinib can be associated with cardiac toxicity. Whether these agents should be restarted in patients who experience cardiac ischemia remains uncertain. Here, we present three patients with metastatic RCC who restarted sunitinib or axitinib after intervention of active ischemic cardiac disease without causing subsequent relevant cardiac events. This experience suggests that these agents can be continued after management of cardiac ischemia.http://dx.doi.org/10.1155/2015/817578 |
| spellingShingle | Bo Zhao Laura S. Wood Karen James Brian I. Rini Is It Safe to Restart Antivascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma after Cardiac Ischemia? Case Reports in Oncological Medicine |
| title | Is It Safe to Restart Antivascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma after Cardiac Ischemia? |
| title_full | Is It Safe to Restart Antivascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma after Cardiac Ischemia? |
| title_fullStr | Is It Safe to Restart Antivascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma after Cardiac Ischemia? |
| title_full_unstemmed | Is It Safe to Restart Antivascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma after Cardiac Ischemia? |
| title_short | Is It Safe to Restart Antivascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma after Cardiac Ischemia? |
| title_sort | is it safe to restart antivascular endothelial growth factor therapy in patients with renal cell carcinoma after cardiac ischemia |
| url | http://dx.doi.org/10.1155/2015/817578 |
| work_keys_str_mv | AT bozhao isitsafetorestartantivascularendothelialgrowthfactortherapyinpatientswithrenalcellcarcinomaaftercardiacischemia AT lauraswood isitsafetorestartantivascularendothelialgrowthfactortherapyinpatientswithrenalcellcarcinomaaftercardiacischemia AT karenjames isitsafetorestartantivascularendothelialgrowthfactortherapyinpatientswithrenalcellcarcinomaaftercardiacischemia AT brianirini isitsafetorestartantivascularendothelialgrowthfactortherapyinpatientswithrenalcellcarcinomaaftercardiacischemia |